Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Regulus To Go Public After Two Deals
by Ann M. Thayer
August 27, 2012
| A version of this story appeared in
Volume 90, Issue 35
Regulus Therapeutics has filed for an initial public offering of up to $58 million in stock after signing two drug development deals. Founded in 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals, San Diego-based Regulus develops oligonucleotide drugs to regulate microRNAs. AstraZeneca will pay $28 million for an equity stake in Regulus and to support research on oncology and cardiovascular and metabolic disease targets. Biogen Idec will invest in Regulus and work with it to identify microRNAs as biomarkers for multiple sclerosis.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter